Business Wire

Exasol Announces Expanded Capabilities of Its Analytics SaaS Database, Including ETL Integration

3.5.2022 11:00:00 EEST | Business Wire | Press release

Share

Exasol, the market leading high-performance analytics database, has announced that from today, Exasol SaaS – the scalable, consumption-based SaaS database based on Amazon Web Services (AWS) – now natively interfaces with Keboola, a cloud-based Data Stack as a Service platform. Keboola provides the first complete solution for data engineers, data analysts, and analytics engineers to deliver on the full spectrum of data demands – from data ingestion to automation. Users will benefit from a built-in function that connects them directly to Keboola from Exasol’s SaaS interface. The Keboola low-code platform provides more than 250 integrations for building ETL/ELT and other pipelines, automation, one-click workflows with integrated business case templates, as well as enterprise grade data governance over the entire stack. It’s a combination that provides improved data accuracy and reduces the time to value.

Commenting on the news, Milan Veverka, VP of Alliances at Keboola said: “We believe that by surrounding ourselves with amazing people, we can achieve anything. That's why we focus on building partnerships that matter. Partnerships with companies that have a similar mindset as we do - empowering everyone to make data-driven decisions. Keboola and Exasol provide great solutions together. We built a simple to use, cost-effective and easy to maintain Data Stack as a Service while Exasol provides its fast in-memory database that helps customers to get to their solution. Together we will make both the implementation and the queries themselves much faster for shared customers.”

In addition to the new collaboration with Keboola, Exasol has introduced a series of new product capabilities that expand on its fully managed, SaaS offering. The new product capabilities will further enhance a customer’s ability to access data-led insights quickly, without needing to manage hardware infrastructures. These innovations include:

  • Enhanced AI/ML capabilities: Customers can now solve complex analytics challenges with ease, such as predictive analytics, by bringing in AI/ML algorithms directly to the data. Operationalizing ML models will also bring maximum performance within the database to its users.
  • Data virtualization support: Analysts will be able to access objects from external sources without the need for migrating data. This support will also eliminate the need for the costly management of duplicate data. It will allow users to more easily access their data – whether it’s stored locally or in the cloud – and set-up or create a logical data warehouse.
  • Amazon SageMaker extension: Exasol SaaS now supports a SageMaker Extension, enabling users to develop end-to-end machine learning projects on data stored in Exasol using the Amazon SageMaker Autopilot service. Doing so mean users can turn data into actionable insights in a matter of minutes.

“When it comes to an organization’s data strategy, data leaders are looking for the confidence to modernize with market-proven, enterprise capabilities that offer flexible migration paths – often to the cloud – at a pace and time that fits with budget and resource constraints,” says Donald Kaye, Chief Commercial Officer at Exasol. The impact of this decision can be profound: affecting costs, the pace of innovation, production releases, marketing penetration and security, to name just a few. “To address the complex challenges organizations face when looking to garner actionable insight from their data, we announced, in February, the strengthening of our hybrid cloud proposition by making our high-performance analytics database available via Exasol SaaS.”

Exasol SaaS is available in two versions. The Exasol SaaS Standard Edition delivers industry leading performance on-demand for organizations with smaller data volumes who don’t require advanced analytics and data integration features or extended support. The Exasol SaaS Enterprise Edition is designed for organizations that require multi-departmental analytics environments, need to perform ML or AI in the database, or have complex requirements in terms of data integration and data virtualization.

Both versions of Exasol SaaS are available here.

About Exasol

Exasol was founded in 2000 with the vision to transform how organizations use data. Today, Exasol’s analytics database – the fastest in the world – is trusted by the world’s most ambitious organizations. With offices in several locations across the US and Europe, Exasol is committed to delivering flexible, scalable and powerful analytics solutions to customers wherever they are, in the cloud – public or private - or on-premises.

Exasol – the leading Performance Analytics Database powering insights from the world’s data.

Learn more at: www.exasol.com and follow us on social media: LinkedIn and Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Isabella Alder, EMEA PR Manager at Exasol

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye